What were the main drivers of Merck's sales growth in the third quarter of 2022?

Merck's sales growth in the third quarter of 2022 was primarily driven by strong performance in its oncology franchise, particularly Keytruda, and significant contributions from Lagevrio (molnupiravir) in the virology segment. Growth in the vaccines franchise, led by Gardasil and Gardasil 9, and hospital acute care products like Bridion also contributed positively. Higher revenue from third-party manufacturing arrangements further supported sales.

How did R&D expenses change, and what were the key reasons for the change?

Research and Development (R&D) expenses increased substantially to $4.4 billion in the third quarter of 2022 from $2.4 billion in the prior year period. This increase was mainly due to an $887 million intangible asset impairment charge related to nemtabrutinib, higher charges associated with collaborations and licensing agreements (including payments to Orion, Moderna, and Orna), increased clinical development spending, and investments in technology. The increase in R&D expenses was partially offset by a significant charge in the prior year related to the acquisition of Pandion Therapeutics.

What is Merck's outlook regarding the impact of the Inflation Reduction Act?

Merck anticipates that the Inflation Reduction Act (IRA) will negatively affect sales and profits. Specifically, the IRA introduces penalties for drug price increases exceeding inflation, redesigns the Medicare Part D program with greater manufacturer liability for drug benefits, and allows for government price setting for certain Medicare Part B and Part D drugs starting in 2026 and 2028, respectively.

What are the company's plans regarding share repurchases and dividends?

Merck's Board of Directors authorized up to $10 billion in share repurchases, with approximately $5.0 billion remaining authorization as of September 30, 2022. The company did not repurchase any shares in the third quarter of 2022. Merck paid $5.3 billion in dividends to stockholders in the first nine months of 2022, reflecting its commitment to returning capital to shareholders. The quarterly dividend was $0.69 per share for Q3 and Q4 2022.

MRK 10-Q Quarterly Report Q3 FY2022 — Revenue, Net Income, EPS

Summary

Merck & Co., Inc. (MRK) reported strong third-quarter and year-to-date results for 2022, showcasing significant sales growth driven by Keytruda and Lagevrio. Total sales increased by 14% in the third quarter to $14.96 billion and by 29% for the first nine months to $45.45 billion. This growth was primarily fueled by a robust performance in the oncology franchise, led by Keytruda, and substantial contributions from Lagevrio in the virology segment. The company also saw positive momentum in its vaccines and hospital acute care products. Despite these strong top-line results, the company is navigating ongoing pricing pressures and global economic uncertainties, including the impact of the war in Ukraine, which, however, remained immaterial to the financial statements for the period. Merck's strategic investments in research and development, particularly in oncology and other key therapeutic areas, continue to drive its pipeline. The company is also managing its cost structure through restructuring initiatives, aiming for long-term efficiency. Overall, Merck demonstrates financial resilience and strategic focus amidst a dynamic market environment.

Financial Highlights

55 data points

Beta

Revenue

$14.96B

0.7% Gross Margin

Net Income

$3.25B

0.2% Net Margin

EPS (Diluted)

$1.28

Total Assets

$107.08B

Cash & Equivalents

$11.14B

Free Cash Flow

$2.36B

Financial Statements

Beta

Revenue	$14.96B
Cost of Revenue	$3.93B
Gross Profit	$11.03B
R&D Expenses	$4.40B
SG&A Expenses	$2.52B
Operating Income	$11.50B
Interest Expense	$244.00M
Net Income	$3.25B
EPS (Basic)	$1.28
EPS (Diluted)	$1.28
Shares Outstanding (Basic)	2.53B
Shares Outstanding (Diluted)	2.54B

Key Highlights

1Total sales increased by 14% to $14.96 billion in Q3 2022 and by 29% to $45.45 billion for the first nine months of 2022, driven by strong performance across key franchises.
2The Oncology franchise saw significant growth, with Keytruda sales up 20% in Q3 and alliance revenues from Lynparza, Lenvima, and Reblozyl also contributing positively.
3Lagevrio sales were a major driver, contributing $436 million in Q3 and $4.86 billion year-to-date, underscoring its importance in the COVID-19 treatment landscape.
4Vaccines, particularly Gardasil/Gardasil 9, showed robust growth, up 15% in Q3 and 31% year-to-date, driven by strong demand in international markets.
5Research and Development expenses increased significantly, primarily due to an $887 million intangible asset impairment charge related to nemtabrutinib, alongside increased collaboration and licensing payments.
6Merck's balance sheet remains strong with $11.15 billion in cash and cash equivalents and $984 million in investments as of September 30, 2022.
7The company continues to manage its cost base through ongoing restructuring programs, with expected annual net cost savings of approximately $900 million by the end of 2023.

Merck & Co., Inc. Quarterly Report for Q3 Ended Sep 30, 2022

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions